Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Licenses Stroke-Related Gene IP to Celera Diagnostics

NEW YORK, Jan. 15-Celera Diagnostics has secured a license to Variagenics' patents on a set of polymorphisms in a gene related to thromboembolic disease risk, Variagenics said yesterday.

 

The license, which is global and non-exclusive, allows Celera Diagnostics to commercialize products that detect variations in the gene for methylenetetrahydrofolate reductase, which has been associated with cardiovascular disease, myocardial infarction and stroke.

 

Celera plans to develop analyte specific reagents and, ultimately, in vitro diagnostics.

 

The companies did not reveal financial details of the agreement.

 

The gene may also be important in central nervous system disease, osteoporosis, folic acid metabolic diseases, and cancer, and Variagenics will retain the right to develop pharmacogenomic tests for these illnesses.

 

Variagenics acquired patent rights for MTHFR from McGill University in 1999, and researchers at the university and the company have continued to work together to find pharmacogenomic markers associated with the gene.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.